Supportive Care (scrambler therapy, sensory test, gait test) for Peripheral Neuropathy

N/A

Waitlist Available

Led By Salahadin Abdi

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to the last day of 2-week treatment

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing how well a new pain-blocking treatment works for people with cancer who have pain from chemotherapy.

Eligible Conditions

Cancer
Peripheral Neuropathy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to the last day of 2-week treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to the last day of 2-week treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to the last day of 2-week treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Chemotherapy induced peripheral neuropathic pain (CIPN) score difference

Secondary study objectives

Change in cancer-related symptoms

Change in physical function and quality of life

Change in therapy-induced neuropathy

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Supportive Care (scrambler therapy, sensory test, gait test)Experimental Treatment6 Interventions

Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

FitBit

2017

N/A

~480

Quantitative Sensory Testing

2017

N/A

~950